Literature DB >> 3103217

Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes.

J S Flier, M M Mueckler, P Usher, H F Lodish.   

Abstract

An accelerated rate of glucose transport is among the most characteristic biochemical markers of cellular transformation. To study the molecular mechanism by which transporter activity is altered, cultured rodent fibroblasts transfected with activated myc, ras, or src oncogenes were used. In myc-transfected cells, the rate of 2-deoxy-D-glucose uptake was unchanged. However, in cells transfected with activated ras and src oncogenes, the rate of glucose uptake was markedly increased. The increased transport rate in ras- and src-transfected cells was paralleled by a marked increase in the amount of glucose transporter protein, as assessed by immunoblots, as well as by a markedly increased abundance of glucose transporter messenger RNA. Exposure of control cells to the tumor-promoting phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) for 18 hours had a similar effect of increasing the rate of glucose transport and the abundance of transporter messenger RNA. For ras, src, and TPA, the predominant mechanism responsible for activation of the transport system is increased expression of the structural gene encoding the glucose transport protein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103217     DOI: 10.1126/science.3103217

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  207 in total

Review 1.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

2.  Characterization of the intracellular signalling pathways that underlie growth-factor-stimulated glucose transport in Xenopus oocytes: evidence for ras- and rho-dependent pathways of phosphatidylinositol 3-kinase activation.

Authors:  F J Thomson; T J Jess; C Moyes; R Plevin; G W Gould
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

3.  Regulation of collagen I gene expression by ras.

Authors:  J L Slack; M I Parker; V R Robinson; P Bornstein
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

4.  Possible mechanism by which stress accelerates growth of virally derived tumors.

Authors:  L M Romero; K M Raley-Susman; D M Redish; S M Brooke; H C Horner; R M Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

5.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

6.  Transcriptional activation of the CEF-4/9E3 cytokine gene by pp60v-src.

Authors:  M Dehbi; A Mbiguino; M Beauchemin; G Chatelain; P A Bédard
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

7.  Restricted expression of the erythroid/brain glucose transporter isoform to perivenous hepatocytes in rats. Modulation by glucose.

Authors:  M Tal; D L Schneider; B Thorens; H F Lodish
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

Review 8.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

9.  Possible involvement of normal p21 H-ras in the insulin/insulinlike growth factor 1 signal transduction pathway.

Authors:  B M Burgering; A J Snijders; J A Maassen; A J van der Eb; J L Bos
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

10.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.